References
- David J., Vouyiouka O., Ansell B. M., Hall A., Woo P. Amyloidosis in chronic juvenile arthritis: a morbidity and mortality study. Clin Exp Rheum 1993; 11: 85–90
- Filipowicz‐Sosnowska A. M., Rozropwicz‐Denisiewicz K., Rosenthal C. J., Baum J. The amyloidosis of juvenile rheumatoid arthritis: comparative studies in Polish and American children. Arthitis Rheum 1978; 37: 699–703
- Ozdogan H., Kasapcopur O., Dede H., Arisoy N., Beceren T., Yurdakul S., et al. Juvenile chronic arthritis in a Turkish population. Clin Exp Rheumatol 1991; 9: 431–5
- Ylijoki H. Re‐evaluation of the factors determining the long‐term clinical outcome of juvenile rheumatoid arthritis [in Finnish with English summary]. Turku: The Social Insurance Institution, Finland, Studies in Social Security and Health 1998; 31: 1–135
- Savolainen H. A., Isomaki H. A. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 1201–3
- Savolainen H. A. Chlorambucil in severe juvenile chronic arthritis: long‐term follow‐up with special reference to amyloidosis. J Rheumatol 1999; 26: 898–903
- Savolainen H. A., Kautiainen H., Isomäki H., Aho K., Verronen P. Azathioprine in patients with juvenile chronic arthritis: a long‐term follow‐up study. J Rheumatol 1997; 24: 2444–50
- Haapasaari J. Disease modifying drug treatment in juvenile idiopathic arthritis. Academic Dissertation. Acta Universitatis Tamperensis 2006; 1158